STEPHANIE PETTINGLE: Open Payments
NPI 1205258605 · SHELTON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$377 in 16 payments from 7 companies in 2025. Trend: 2023 $75 · 2024 $275 · 2025 $377
Food & beverage: $377
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $138 |
| Lilly USA, LLC | 4 | $96 |
| Astellas Pharma US Inc | 2 | $60 |
| ABBVIE INC. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| SANOFI-AVENTIS U.S. LLC | 1 | $18 |
Products named: MOUNJARO, Veozah, UBRELVY, Wegovy, CAPLYTA, XIFAXAN, Ozempic, TZIELD.
Industry payments across CT — which companies pay providers there.
